| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 5277- | 3BP, | 3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model |
| - | in-vivo, | PC, | Panc02 |
| 5276- | 3BP, | A Translational Study 'Case Report' on the Small Molecule 'Energy Blocker' 3-Bromopyruvate (3BP) as a Potent Anticancer Agent: From Bench Side to Bedside(2012) |
| - | Case Report, | HCC, | NA |
| 5274- | 3BP, | ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 |
| - | in-vitro, | PC, | NA |
| 5263- | 3BP, | CET, | 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | HCT116 |
| 5259- | 3BP, | Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP |
| - | in-vivo, | HCC, | NA |
| 5260- | 3BP, | Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer |
| - | in-vivo, | PC, | NA |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 5270- | 5-ALA, | PDT, | 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy |
| - | Review, | Var, | NA |
| 5302- | 5-HTP, | Hippocampal ischaemia from accidental 5-Hydroxytryptophan (5-HTP) overdose case report |
| - | Case Report, | Nor, | NA |
| 5310- | 5-HTP, | 5-Hydroxytryptophan toxicity successfully treated by haemodialysis in a dog |
| - | Case Report, | Nor, | NA |
| 5303- | 5-HTP, | 5-HTP shows early promise for cognitive support and in seniors: Singapore study |
| - | Trial, | AD, | NA |
| 5298- | 5-HTP, | Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa |
| - | Human, | AD, | NA |
| 5306- | 5-HTP, | Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level |
| - | Trial, | AD, | NA |
| 5307- | 5-HTP, | 5-Hydroxytryptophan toxicosis in dogs: 1989-1999 |
| - | Case Report, | Nor, | NA |
| 5466- | AF, | Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer |
| - | in-vivo, | Lung, | NA |
| 5463- | AF, | Will Auranofin Become a Golden New Treatment Against COVID-19? |
| - | Review, | Covid, | NA |
| 5462- | AF, | Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy |
| - | Review, | Var, | NA |
| 5457- | AF, | Clinical pharmacokinetics of oral and injectable gold compounds |
| - | Human, | Nor, | NA |
| 5456- | AF, | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent |
| - | Trial, | Nor, | NA |
| 5455- | AF, | Ridaura |
| - | Study, | PSA, | NA |
| 5470- | AF, | Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin |
| - | Review, | Var, | NA |
| - | in-vitro, | Lung, | NA |
| 5444- | AG, | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine |
| - | Review, | Var, | NA |
| 5443- | AG, | Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers |
| - | Human, | Nor, | NA |
| 5435- | AG, | Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies |
| - | Review, | Var, | NA |
| 4402- | AgNPs, | Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors |
| - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4400- | AgNPs, | Rad, | Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | BC, | MDA-MB-231 |
| 4439- | AgNPs, | Anticancer Potential of Green Synthesized Silver Nanoparticles Using Extract of Nepeta deflersiana against Human Cervical Cancer Cells (HeLA) |
| - | in-vitro, | Cerv, | HeLa |
| 4447- | AgNPs, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
| 4560- | AgNPs, | Exploiting antidiabetic activity of silver nanoparticles synthesized using Punica granatum leaves and anticancer potential against human liver cancer cells (HepG2) |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Diabetic, | NA |
| 4600- | AgNPs, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 4598- | AgNPs, | In vivo human time-exposure study of orally dosed commercial silver nanoparticles |
| - | in-vivo, | Nor, | NA |
| 4582- | AgNPs, | Silver CASRN 7440-22-4 | DTXSID4024305 |
| 4579- | AgNPs, | Response of platelets to silver nanoparticles designed with different surface functionalization |
| 4577- | AgNPs, | Characterization of Antiplatelet Properties of Silver Nanoparticles |
| - | vitro+vivo, | Stroke, | NA |
| 375- | AgNPs, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 305- | AgNPs, | Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer |
| - | Case Report, | HNSCC, | NA |
| 2835- | AgNPs, | Gluc, | Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake |
| - | in-vitro, | Liver, | HepG2 |
| 2834- | AgNPs, | Gluc, | Electrochemical oxidation of glucose on silver nanoparticle-modified composite electrodes |
| - | Study, | NA, | NA |
| 2206- | AgNPs, | RES, | ENHANCED EFFICACY OF RESVERATROL-LOADED SILVER NANOPARTICLE IN ATTENUATING SEPSIS-INDUCED ACUTE LIVER INJURY: MODULATION OF INFLAMMATION, OXIDATIVE STRESS, AND SIRT1 ACTIVATION |
| - | in-vivo, | Nor, | NA |
| 2205- | AgNPs, | Potential protective efficacy of biogenic silver nanoparticles synthesised from earthworm extract in a septic mice model |
| - | in-vivo, | Nor, | NA |
| 5353- | AL, | Aged Garlic Extract May Be Safe for Patients on Warfarin Therapy |
| - | Human, | Nor, | NA |
| 2560- | AL, | Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease |
| - | ex-vivo, | Nor, | NA |
| 2666- | AL, | Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals |
| - | Review, | Var, | NA |
| 1916- | AL, | Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods |
| - | Review, | Nor, | NA |
| 257- | AL, | Cisplatin, | Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors |
| - | in-vitro, | NSCLC, | A549 |
| 3539- | ALA, | Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential |
| - | Review, | AD, | NA |
| 281- | ALA, | Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation |
| - | in-vitro, | Lung, | H460 |
| 304- | ALA, | alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation |
| - | in-vitro, | Colon, | HT-29 |
| 267- | ALA, | α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | PC9 |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid